1Yang S H, Dou K F, Song W J, et al.Prevalence of diabetes among men and omen in China[J].N Engl J Med, 2010, 362(25): 2425-2426.
2Cryer P E.The barrier of hypoglycemia in diabetes[J].Diabetes, 2008, 57(26: 3169-3176.
3Cryer P E.Elimi nation of hypoglycemia from the lives of people affected by diabetes[J].Diabetes, 2011, 60(45): 24-27.
4Amiel S A, Dixon T, Mann R, et al.Hypoglycaemia in type 2 diabetes[J]. DiabetMed, 2008, 35(25): 245-254.
5Campbell R.G|imepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus[J].Ann Pharmacother, 1998, 32(10): 1044-1052.
6Schernthaner G, Grimaldi A, Di Mario U, et aI.GUIDE study: double- blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabeticpatients[J].EurJClinInvest, 2004, 34(26): 535-542.
7Gough S C.A review of human and analogue insulin trials[J].Diabetes Res ClinPract, 2007, 56(770:1-15.
8Hirsch I B.Insulin analogues[J].N Engl J Med, 2005, 98(352): 174-183.
9Horvath K, Jeitler K, Berghold A, et al.Long-acting insulin analogues versus NPH insulin ( human isophane insulin) for type 2 diabetes mellitus[J].Cochrane Database Syst Rev, 2007, 26(25): 5613.
10Riddle M C, Rosenstock J, Gerich J.The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care, 2003, 26(2): 3080-3086.
8Matuda M, Shimomura L,Sata M,et al. Role of adiponectinin preventing vascular stenosis the missing link of adipo-vascular axis[J]. J Biol Chem, 2002,277 (40) ; 37486-37491.
9Denjalic A,Beculic H’Jusic A,et al. Evaluation of the sur-gical treatment of diabetic foot[J]. Med Glas,2014,11 (2):307-312.
10Liu X,Fan Z, Zhang N,et al. Unenhanced MR angiogra-phy of foot : Initial experience of using flow-sensitive de-phasing-prepared steady-state free precession in patientswith diabetes[J]. Radiology, 2014,272(3) : 885-894.
